Pharmaceuticals collaborations
“A wellspring of innovation exists in the global effort to discover new ways to treat and prevent disease. We recognise that leading-edge science lies both within and outside of GSK’s R&D labs. Externalisation is key to our R&D strategy and we have a solid track record of successful collaborations that ultimately help bring new medicines of value to improve patients’ lives.”
- Ian Tomlinson
Senior Vice President,
Worldwide Business Development & Biopharmaceuticals R&D
As a science-led, global pharmaceutical company, our research and development (R&D) Business Development group is committed to accessing innovative medicines to treat a broad range of diseases.
We understand the value of partnering. We always look for creative and mutually beneficial pharmaceutical collaborations that provide the best value in medicines to patients and to the healthcare industry.
How we work
Across Pharmaceuticals R&D, our therapeutically-embedded Business Development teams drive the strategies developed by the various R&D areas. We have dedicated global Business Development professionals to work with you throughout the business development process - from due diligence to negotiations and deal management.
How we can help you
The best science is the foundation of all our alliance partnerships, and it drives our flexible approach to collaborative business models. Our approach includes early stage option-based deals, late stage licensing deals, and acquisitions.
Our alliance management teams manage assets from early stage through to marketed products, and across a wide range of collaboration structures. Alliance management helps to connect our partners with the broader community within GSK and drives smooth deal execution throughout the collaborative relationship.
Take advantage of our global network of resources
The entire GSK business development team has access to the wide capabilities of our global organization to support our partnerships. An example of a unique resource that can be tapped into is our R&D-based Scinovo group. Scinovo represents GSK's commitment to partnering through a dedicated scientific support model that facilitates access to our preclinical and drug development expertise. For more information, visit the Scinovo website.
Our areas of interest
We are currently actively seeking collaborations in the following areas of research:
- metabolic and cardiovascular
- immune-inflammation
- infectious diseases
- neurosciences
- ophthalmology
- respiratory
- rare diseases
- oncology
- HIV (through our joint venture company ViiV Healthcare)
- dermatology (through our skin care company Stiefel)
- platform technologies
To find out more about our areas of interest and the regions in which we operate, view our Commercial opportunities page.